Darryl Turner, NP
Acute Care · Ringgold, GANPI 1982986279
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 84.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $19,302 and has fallen 93.5% since, to $1,261 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $197.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$18K
- Boston Scientific$2K
- Sumitomo Pharma America, Inc.$252
- Axonics, Inc.$194
- AbbVie$181
- Urogen Pharma, Inc.$163
- plus $873 from 17 others
What the payments were for
- Consulting fees$7293%
- Speaking & faculty fees$11,41854%
- Travel & lodging$5,98729%
- Food & beverage$2,83414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $17,805 |
| Boston Scientific | 11 | $1,500 |
| Sumitomo Pharma America, Inc. | 12 | $252 |
| Axonics, Inc. | 3 | $194 |
| AbbVie(2 entities) | 7 | $181 |
| Urogen Pharma, Inc. | 6 | $163 |
| Laborie Medical Technologies Corp. | 2 | $109 |
| SRS Medical Systems, Inc. | 1 | $107 |
| Progenics Pharmaceuticals, Inc. | 4 | $90 |
| Dendreon Pharmaceuticals LLC | 3 | $85 |
| Pfizer | 4 | $81 |
| Endo USA, Inc. | 3 | $63 |
| Antares Pharma, Inc. | 4 | $58 |
| Endo Pharmaceuticals Inc. | 3 | $55 |
| Astellas Pharma US Inc | 2 | $55 |
| 180 Medical, Inc. | 1 | $30 |
| Teleflex LLC | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Coloplast | 1 | $17 |
| Photocure Inc | 1 | $16 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,968 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 20 | $18,907 |
| MyrbetriqMirabegron | 25 | $15,964 |
| Tamsulosin Hcl | 182 | $3,033 |
| Testosterone Cypionate | 46 | $1,776 |
| NitrofurantoinNitrofurantoin Macrocrystal | 26 | $1,157 |
| Methenamine Hippurate | 17 | $667 |
| Cefdinir | 26 | $417 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $381 |
| Finasteride | 32 | $381 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $380 |
| Doxycycline Monohydrate | 28 | $346 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $258 |
| Ciprofloxacin Hcl | 63 | $240 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $183 |
| Oxybutynin Chloride | 12 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $252 | $18,90720 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $15,96425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Ringgold
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
- Ayeshia PowellAtlanta$10K
- Mitzi WilliamsGainesville$10K
- Sally WatkinsColumbus$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.